# Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects

> **NCT05619536** · PHASE1 · COMPLETED · sponsor: **Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 28 (actual)

## Conditions studied

- Healthy

## Interventions

- **COMBINATION_PRODUCT:** CD388 Injection
- **DRUG:** Saline placebo

## Key facts

- **NCT ID:** NCT05619536
- **Lead sponsor:** Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-18
- **Primary completion:** 2023-07-14
- **Final completion:** 2023-07-14
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05619536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05619536, "Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05619536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*